uniQure
QURE
173 hedge funds and large institutions have $838M invested in uniQure in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 52 increasing their positions, 63 reducing their positions, and 29 closing their positions.
86% more call options, than puts
Call options by funds: $31.3M | Put options by funds: $16.9M
2.61% more ownership
Funds ownership: 85.96% → 88.57% (+2.6%)
3% less funds holding
Funds holding: 178 → 173 (-5)
8% less capital invested
Capital invested by funds: $912M → $838M (-$73.7M)
10% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 29
17% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 63
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
Top Sellers
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$12.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$11.1M |
| 3 |
Millennium Management
New York
|
-$8.38M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$4.93M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$4.03M |
QURE Hedge Fund Activity: Q1 2023 in Review
173 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in uniQure (QURE) for Q1 2023, worth a combined $838M — down 8.1% from $912M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of QURE and 26 opened new positions — a net loss of 3 holders — while 63 trimmed existing stakes and 52 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $18.2M. The largest seller was MPM BioImpact, cutting an estimated $12.4M.
- 173 institutional investors held uniQure (QURE) as of Q1 2023, down from 178 in Q4 2022.
- Funds reported $838M of uniQure stock for Q1 2023, down 8.1% quarter-over-quarter.
- 26 funds opened new uniQure positions in Q1 2023 and 29 closed out, a net change of -3 holders.
- The largest uniQure buyer in Q1 2023 was Deep Track Capital, an estimated $18.2M added.
- The largest uniQure seller in Q1 2023 was MPM BioImpact, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2023.